Australia: Recent Patent Office decision highlights the importance of identifying patent applications eligible for a pharmaceutical patent term extension

The term of an Australian pharmaceutical patent may be extended if a product covered by the claims receives regulatory approval in Australia. An extension of the term of a patent can be worth literally hundreds of millions of dollars to the patentee. Consequently, this is an area of Australian patent law that is of significant commercial interest.

The patent term extension (PTE) provisions were introduced to compensate for the loss of "effective" pharmaceutical patent life due to (a) lengthy drug development periods, and (b) the need to obtain regulatory approval which delays entry of the product onto the market. Accordingly, an Australian patent may be eligible for an extension of term if more than 5 years elapses between the date of filing of the patent and the date of first inclusion on the Australian Register of Therapeutic Goods (ARTG) of goods containing or consisting of the patented pharmaceutical substance.

Importantly, an application for a PTE must be lodged within 6 months from the later of the following dates:

  1. the date the patent was granted;
  2. the date of first inclusion in the ARTG of a pharmaceutical substance covered by the patent.

In the event that a PTE application is not filed by the relevant deadline, it is possible to request an extension of time, under Section 223, in which to perform an "act" when the "act" was not carried out at the appropriate time due to an error or omission on the part of the applicant or their attorney. Given the potential value of the PTE, it may be well worth pursuing an extension of time in which to make the appropriate request.

Mount Sinai School of Medicine [2013] APO 52 (5 September 2013)


A recent Australian Patent Office decision, Mount Sinai School of Medicine [2013] APO 52 (5 September 2013) considered an application for an extension of time for the purpose of extending the period for filing a PTE application. The period of extension sought was 9 years and 11 months, from 17 November 2002 to 17 October 2012.

The patent-in-suit, AU691795, in the name of Mount Sinai School of Medicine (MSSM) and licensed exclusively to Genzyme Corporation (Genzyme), is directed to methods of producing a-galactosidase A (REPLAGAL/FABRAZYME). It is due to expire on 30 November 2013.

In the decision it was indicated that the potential PTE based on the date of the patent (30 November 1993) and the date of first inclusion on the ARTG of the product REPLAGAL (17 May 2002), is the maximum period of 5 years. However, this appears to be an error. The term of a PTE, according to s77 of Patents Act 1990, is equal to the period from the date of the patent to the earliest regulatory approval date, less five years. In the present case this period is 3 years, 5 months and 17 days.


The evidence submitted by MSSM attempted to persuade the Deputy Commissioner of Patents that the failure to file a PTE application occurred as a result of an error or omission within s223 and that absent the error or omission, a PTE application would have been filed for the Australian patent prior to the relevant deadline.

Initially, MSSM submitted declaratory evidence that they relied, in 2002, on the licensee (in the present case, Genzyme) to inform them of the status of regulatory approval of any pharmaceutical products covered by a patent. When notification of marketing authorisation of the product in a particular country was received this would "initiate the decision making process for whether or not to extend the patent".

However in a second declaration MSSM stated, contrary to the first declaration, that they did not have a general practice in relation to PTEs in November 2002 and that this was developed subsequently. Rather, MSSM relied on the responsible attorneys in different jurisdictions to provide advice in relation to the relevant laws and procedures for their patents. In this regard, a declaration prepared by the Australian attorneys responsible for the prosecution of the patent (Phillips Ormonde Fitzpatrick (POF)) states that they did not in any correspondence prior to April 2012 state that the patent may qualify for an extension of term.

Thus, the evidence submitted appears to suggest that either one of two errors resulted in the failure to file the application for PTE namely, the failure of Genzyme to inform MSSM about the status of the relevant regulatory approval and/or the failure of the Australian attorneys to provide advice regarding the eligibility of the patent for a PTE. The extension of the equivalent US patent was put forward as being indicative of MSSM's likely intention to extend the Australian patent.


The Deputy Commissioner of Patents found that while an error or omission may have occurred, the evidence did not address the circumstances that existed at the relevant time in a full and frank manner. This suggested a significant possibility that MSSM only recently determined that an extension of term was desirable and that there was no real intention to extend the patent before the relevant date.

In relation to the alleged error that Genzyme had failed to inform MSSM of the ARTG listing for FABRAZYME, the Deputy Commissioner of Patents found that the evidence indicated that Genzyme had no such obligation and that the trigger in Australia was in fact the listing of REPLAGAL not FABRAZYME.

Regarding the failure of the Australian attorneys, Phillips Ormonde and Fitzpatrick (POF), to provide advice about a possible PTE, the Deputy Commissioner of Patents stated that until the listing of REPLAGAL in 2002, an extension of time could not have been requested. Thus, it was considered that the failure of POF to provide relevant advice regarding PTE would only be significant if the advice would have prompted MSSM to put in place processes for monitoring the ARTG for the inclusion of goods containing a-galactosidase A. However, the Deputy Commissioner of Patents found that there was insufficient evidence to conclude that such advice would have made a difference to MSSM's actions.

The Deputy Commissioner of Patents also found that the evidence and surrounding circumstances did not show a "demonstrated desire" to obtain an extension of term in Australia. The obtaining of an extension for the equivalent US patent was considered to be suggestive that a decision to seek extension may have been made but it was also considered that there might have been reasons why the decision would have been different, such as the different commercial value of FABRAZYME in Australia. In this regard, evidence detailing the specific importance of obtaining a term extension in Australia was not provided.

Ultimately, it was considered that significant unanswered doubts existed that MSSM, in the relevant period, intended to obtain a PTE in Australia and failed to do so due to an error or omission. On this basis the application for an extension of time to file the PTE was refused.

The extension of time application was also refused on discretionary grounds because it was found that the patentee and its agents had unreasonably protracted the uncertainty concerning the term of the patent close to the end of its term.

Concluding comments

The above Patent Office decision highlights the importance for vigilance in relation to patent applications and patents claiming subject matter that potentially falls within the eligibility criteria for a PTE.

In order to obtain a PTE, the patent must relate to a pharmaceutical substance per se or a pharmaceutical substance when produced by recombinant DNA technology. The pharmaceutical substance must be disclosed in the specification and must fall within the scope of the claims.

It is notable that the claims for AU691795 are directed to methods of producing a-galactosidase A. There are no claims directed to a-galactosidase A per se. Therefore, even in the event that the extension of time to file a PTE was granted by the Patent Office, MSSM may have experienced difficulty having the PTE granted for lack of a claim directed to a pharmaceutical substance per se.

Under Australian law, product-by-process claims are permitted and as the methods defined in AU691795 relate to recombinant DNA technology, it would have been prudent to include relevant product-by-process claim(s) during prosecution of the application.

To ensure that the critical PTE deadlines are not overlooked, Shelston IP offers a service whereby a written reminder is issued on a 6-monthly basis starting from the date of grant of the patent. If you would like to avail of this reminder service, or require further information about obtaining a PTE, please let us know.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP has been awarded the MIP Global Award for Australian IP Firm of the Year 2013.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Grant Shoebridge
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.